Use of blood cells in in-vitro characterisation assays

• Research type

  Research Study

• Full title

  Use of whole blood or leucocyte cones from NHSBT centres (from donated material surplus to clinical requirements) and isolated white blood cells and tumour cells from commercial companies for the characterisation of the effect of therapeutic antibodies on immune cell populations for the treatment of cancer

• IRAS ID

  229951

• Contact name

  Anne Goubier

• Contact email

  anne.goubier@blackbelttx.com

• Sponsor organisation

  Black Belt Therapuetics Limited

• Clinicaltrials.gov Identifier

  N/A, N/A

• Duration of Study in the UK

  3 years, 0 months, 0 days

• Research summary

  Various immune cells will be purified from samples obtained from National Health Service Blood and Transplant, NHSBT, centres (either whole blood or leucocyte cones surplus to clinical requirements) these will then be used to assess the therapeutic potential of a panel of monoclonal antibodies that we are testing for an ability to bind and destroy cancer cells or to control the body’s immune system to recognise and “fight” the abnormal cells.

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  17/EE/0344

• Date of REC Opinion

  5 Sep 2017

• REC opinion

  Further Information Favourable Opinion